Castle Biosciences Earns "Top Workplaces USA Award" for Phoenix, Pittsburgh, and Friendswood!
Learn more at www.CastleBiosciences.com
Castle Biosciences Inc. is growing, and we are looking to hire a full-time Cyber Security Risk and Regulatory Analyst working from our headquarters in Friendswood, TX. with a start date on or before October 1, 2026.
Why Castle Biosciences?
Exceptional Benefits Package:
A DAY IN THE LIFE OF THE Cybersecurity Risk and Regulatory Analyst
REQUIREMENTS
* Please see the full job description at the end of the job ad.
SCHEDULE
On site working from Friendswood, TX. Headquarters. Full-time, exempt. Standard business hours with flexibility as needed to support audit deadlines and regulatory submission timelines.
READY TO JOIN OUR BIOTECH TEAM?
We truly appreciate your time. If this feels like the right opportunity for you, we'd love for you to complete our mobile-friendly application. We're excited to learn more about you and look forward to connecting soon!
Castle Biosciences Awards and Research Developments!
WORK AUTHORIZATION
All candidates must be legally authorized to work in the United States. Currently, Castle Biosciences does not sponsor H-1B visas, OPT, or employment-related visas.
ABOUT CASTLE BIOSCIENCES INC.
At Castle, it all comes down to people. After all, disease doesn't just happen - it happens to people. We believe that disease management and treatment decisions can be better informed through a person's unique biology, which is revealed through the scientific rigor of our innovative, laboratory-developed tests. We are committed to empowering healthcare providers and patients with the goal of improved outcomes.
Every employee at Castle has an impact on patient care, and we work to ensure that everyone finds their work to be both challenging and rewarding We behave with integrity and treat our colleagues with respect and kindness Our culture fosters an environment of trust, transparency, and collaboration We prioritize and encourage internal growth and professional development
Castle Biosciences is an equal opportunity employer as to all protected groups, including protected veterans and individuals with disabilities.
If you have a disability and you believe you need a reasonable accommodation in order to search for a job opening or to submit an online application, please e-mail ReasonableAccommodationsRequest@castlebiosciences.com
This email was created exclusively to assist disabled job seekers whose disability prevents them from being able to apply online. Only messages left for this purpose will be returned. Messages left for other purposes, such as following up on an application or technical issues not related to a disability, will not receive a response.
** No third-party recruiters, please
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
The Company’s innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. Castle currently markets five proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, Barrett’s esophagus, and uveal melanoma.
DecisionDx®-Melanoma, Castle’s test for invasive cutaneous melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors.
DecisionDx®-SCC is the Company’s GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors.
MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions.
TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus.
DecisionDx®-UM, the standard of care in uveal melanoma staging, is Castle's GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer.
Castle Biosciences is based in Friendswood, TX, (a suburb of Houston) and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.
